Adding chemo or immunotherapy before surgery for advanced head and neck cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer called squamous cell carcinoma, which started in the mouth, throat, voice box, or the area behind the nose and mouth.
- Your cancer has come back or not gone away after previous treatment, and your doctor thinks surgery can remove it.
- You have had radiation therapy at least 6 months ago, and you have not had immunotherapy for cancer that has spread.
- You are 18 or older, your kidney and liver function are good, and your blood cell counts are within a certain range.
- You are healthy enough for daily activities (ECOG score 0-2) and do not have serious heart or lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for advanced head and neck cancer in patients who cannot take the drug cisplatin. One group gets radiation plus a targeted drug called cetuximab, the other gets radiation plus standard chemotherapy. The goal is to see which approach works better and is safer for people who are not candidates for cisplatin.
This trial studies whether adding cisplatin (a chemotherapy medicine) to radiation therapy helps people with stage III–IVA squamous cell cancer of the head and neck after they’ve had surgery. It’s meant to lower the risk of the cancer coming back.
This Phase 1 trial tests a new plan that combines immunotherapy with surgery, plus a targeted radiation treatment called IORT. It is for people whose head and neck squamous cell cancer has come back or never fully went away and can be operated on. The goal is to shrink or control the cancer and see how safe the approach is.
This study tests whether adding a new targeted drug called ipatasertib to standard chemoradiation can improve treatment for people with locally advanced head and neck cancer. Ipatasertib may help block a protein that helps cancer grow, possibly making the standard therapy more effective.
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
Hear when a new Locally Recurrent Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.